|
1
|
Duenas-Gonzalez A, Serrano-Olvera A,
Cetina L and Coronel J: New molecular targets against cervical
cancer. Int J Womens Health. 6:1023–1031. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Dasari S, Wudayagiri R and Valluru L:
Cervical cancer: biomarkers for diagnosis and treatment. Clin Chim
Acta. 445:7–11. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Schiffman MH: Recent progress in defining
the epidemiology of human papillomavirus infection and cervical
neoplasia. J Natl Cancer Inst. 84:394–398. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Massad LS, Turyk ME, Bitterman P and
Wilbanks GD: Interferon-alpha and all-trans-retinoic acid
reversibly inhibit the in vitro proliferation of cell lines derived
from cervical cancers. Gynecol Oncol. 60:428–434. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kim KY, Blatt L and Taylor MW: The effects
of interferon on the expression of human papillomavirus oncogenes.
J Gen Virol. 81:695–700. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Koromilas AE, Li S and Matlashewski G:
Control of interferon signaling in human papillomavirus infection.
Cytokine Growth Factor Rev. 12:157–170. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Barnard P, Payne E and McMillan NA: The
human papillomavirus E7 protein is able to inhibit the antiviral
and anti-growth functions of interferon-α. Virology. 277:411–419.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lenschow DJ, Lai C, Frias-Staheli N,
Giannakopoulos NV, Lutz A, Wolff T, Osiak A, Levine B, Schmidt RE,
García-Sastre A, et al: IFN-stimulated gene 15 functions as a
critical antiviral molecule against influenza, herpes, and Sindbis
viruses. Proc Natl Acad Sci USA. 104:1371–1376. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Friedman RM: Clinical uses of interferons.
Br J Clin Pharmacol. 65:158–162. 2008. View Article : Google Scholar :
|
|
10
|
Sadler AJ and Williams BR:
Interferon-inducible antiviral effectors. Nat Rev Immunol.
8:559–568. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhang T, Sun HC, Zhou HY, Luo JT, Zhang
BL, Wang P, Wang L, Qin LX, Ren N, Ye SL, et al: Interferon alpha
inhibits hepatocellular carcinoma growth through inducing apoptosis
and interfering with adhesion of tumor endothelial cells. Cancer
Lett. 290:204–210. 2010. View Article : Google Scholar
|
|
12
|
Shi WY, Cao C and Liu L: Interferon α
induces the apoptosis of cervical cancer HeLa cells by activating
both the intrinsic mitochondrial pathway and endoplasmic reticulum
stress-induced pathway. Int J Mol Sci. 17:pii: E1832. 2016.
View Article : Google Scholar
|
|
13
|
Kim KI, Yan M, Malakhova O, Luo JK, Shen
MF, Zou W, de la Torre JC and Zhang DE: Ube1L and protein
ISGylation are not essential for alpha/beta interferon signaling.
Mol Cell Biol. 26:472–479. 2006. View Article : Google Scholar :
|
|
14
|
Hishiki T, Han Q, Arimoto K, Shimotohno K,
Igarashi T, Vasudevan SG, Suzuki Y and Yamamoto N:
Interferon-mediated ISG15 conjugation restricts dengue virus 2
replication. Biochem Biophys Res Commun. 448:95–100. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Loeb KR and Haas AL: The
interferon-inducible 15-kDa ubiquitin homolog conjugates to
intracellular proteins. J Biol Chem. 267:7806–7813. 1992.PubMed/NCBI
|
|
16
|
Haas AL, Ahrens P, Bright PM and Ankel H:
Interferon induces a 15-kilodalton protein exhibiting marked
homology to ubiquitin. J Biol Chem. 262:11315–11323.
1987.PubMed/NCBI
|
|
17
|
Darb-Esfahani S, Sinn BV, Rudl M, Sehouli
J, Braicu I, Dietel M and Denkert C: Interferon-stimulated gene, 15
kDa (ISG15) in ovarian high-grade serous carcinoma: prognostic
impact and link to NF-κB pathway. Int J Gynecol Pathol. 33:16–22.
2014. View Article : Google Scholar
|
|
18
|
Jeon YJ, Yoo HM and Chung CH: ISG15 and
immune diseases. Biochim Biophys Acta. 1802:485–496. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Burks J, Reed RE and Desai SD: Free ISG15
triggers an antitumor immune response against breast cancer: a new
perspective. Oncotarget. 6:7221–7231. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhao C, Hsiang TY, Kuo RL and Krug RM:
ISG15 conjugation system targets the viral NS1 protein in influenza
A virus-infected cells. Proc Natl Acad Sci USA. 107:2253–2258.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Jeon YJ, Jo MG, Yoo HM, Hong SH, Park JM,
Ka SH, Oh KH, Seol JH, Jung YK and Chung CH: Chemosensitivity is
controlled by p63 modification with ubiquitin-like protein ISG15. J
Clin Invest. 122:2622–2636. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wan XX, Chen HC, Khan MA, Xu AH, Yang FL,
Zhang YY and Zhang DZ: ISG15 inhibits IFN-α-resistant liver cancer
cell growth. BioMed Res Int. 2013:5709092013. View Article : Google Scholar
|
|
23
|
Strander H and Einhorn S: Interferons and
the tumor cell. Biotherapy. 8:213–218. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Pfeffer LM, Dinarello CA, Herberman RB,
Williams BR, Borden EC, Bordens R, Walter MR, Nagabhushan TL,
Trotta PP and Pestka S: Biological properties of recombinant
alpha-interferons: 40th anniversary of the discovery of
interferons. Cancer Res. 58:2489–2499. 1998.PubMed/NCBI
|
|
25
|
Darnell JE Jr, Kerr IM and Stark GR:
Jak-STAT pathways and transcriptional activation in response to
IFNs and other extracellular signaling proteins. Science.
264:1415–1421. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
O'Shea JJ, Gadina M and Schreiber RD:
Cytokine signaling in 2002: new surprises in the Jak/Stat pathway.
Cell. 109(Suppl): S121–S131. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Sainz B Jr, Martín B, Tatari M, Heeschen C
and Guerra S: ISG15 is a critical microenvironmental factor for
pancreatic cancer stem cells. Cancer Res. 74:7309–7320. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Takaoka A, Hayakawa S, Yanai H, Stoiber D,
Negishi H, Kikuchi H, Sasaki S, Imai K, Shibue T, Honda K and
Taniguchi T: Inte gration of interferon-α/β signalling to p53
responses in tumour suppression and antiviral defence. Nature.
424:516–523. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Malakhov MP, Malakhova OA, Kim KI, Ritchie
KJ and Zhang DE: UBP43 (USP18) specifically removes ISG15 from
conjugated proteins. J Biol Chem. 277:9976–9981. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yuan W and Krug RM: Influenza B virus NS1
protein inhibits conjugation of the interferon (IFN)-induced
ubiquitin-like ISG15 protein. EMBO J. 20:362–371. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
D'Cunha J, Knight E Jr, Haas AL, Truitt RL
and Borden EC: Immunoregulatory properties of ISG15, an
interferon-induced cytokine. Proc Natl Acad Sci USA. 93:211–215.
1996. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Owhashi M, Taoka Y, Ishii K, Nakazawa S,
Uemura H and Kambara H: Identification of a ubiquitin family
protein as a novel neutrophil chemotactic factor. Biochem Biophys
Res Commun. 309:533–539. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Campbell JA and Lenschow DJ: Emerging
roles for immunomodulatory functions of free ISG15. J Interferon
Cytokine Res. 33:728–738. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Desai SD, Reed RE, Burks J, Wood LM,
Pullikuth AK, Haas AL, Liu LF, Breslin JW, Meiners S and Sankar S:
ISG15 disrupts cytoskeletal architecture and promotes motility in
human breast cancer cells. Exp Biol Med (Maywood). 237:38–49. 2012.
View Article : Google Scholar
|
|
35
|
Burks J, Reed RE and Desai SD: ISGylation
governs the oncogenic function of Ki-Ras in breast cancer.
Oncogene. 33:794–803. 2014. View Article : Google Scholar
|
|
36
|
Kiessling A, Hogrefe C, Erb S, Bobach C,
Fuessel S, Wessjohann L and Seliger B: Expression, regulation and
function of the ISGylation system in prostate cancer. Oncogene.
28:2606–2620. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Yoshikawa A, Imagawa A, Nakata S, Fukui K,
Kuroda Y, Miyata Y, Sato Y, Hanafusa T, Matsuoka TA, Kaneto H, et
al: Interferon stimulated gene 15 has an anti-apoptotic effect on
MIN6 cells. Endocr J. 61:883–890. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Butz K, Shahabeddin L, Geisen C,
Spitkovsky D, Ullmann A and Hoppe-Seyler F: Functional p53 protein
in human papillomavirus-positive cancer cells. Oncogene.
10:927–936. 1995.PubMed/NCBI
|
|
39
|
Mendonca MS, Howard KL, Farrington DL,
Desmond LA, Temples TM, Mayhugh BM, Pink JJ and Boothman DA:
Delayed apoptotic responses associated with radiation-induced
neoplastic transformation of human hybrid cells. Cancer Res.
59:3972–3979. 1999.PubMed/NCBI
|
|
40
|
Yang J, Dai LX, Chen M, Li B, Ding N, Li
G, Liu YQ, Li MY, Wang BN, Shi XL and Tan HB: Inhibition of
antiviral drug cidofovir on proliferation of human
papillomavirus-infected cervical cancer cells. Exp Ther Med.
12:2965–2973. 2016.PubMed/NCBI
|
|
41
|
Huang YF, Wee S, Gunaratne J, Lane DP and
Bulavin DV: Isg15 controls p53 stability and functions. Cell Cycle.
13:2200–2210. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
42
|
Huang YF and Bulavin DV: Oncogene-mediated
regulation of p53 ISGylation and functions. Oncotarget.
5:5808–5818. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Menendez D and Anderson CW: p53 vs. ISG15:
stop, you're killing me. Cell Cycle. 13:2160–2161. 2014. View Article : Google Scholar : PubMed/NCBI
|
